Understanding the Most Common Side Effects of Polivy (Poliwix)

Introduction to Polivy

Polivy, also known as polatuzumab vedotin-piiq, is a monoclonal antibody-drug conjugate (mAb-ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL). It works by targeting and killing cancer cells that express the CD79b protein. In this article, we will delve into the most common side effects of Polivy and what you can expect during treatment.

What Are the Most Common Side Effects of Polivy?

According to the FDA label and clinical trials, the most common side effects of Polivy include:

*

Nausea and Vomiting

Nausea and vomiting are among the most common side effects of Polivy, affecting up to 90% of patients. These symptoms can be severe and may require medication to manage.
*

Diarrhea

Diarrhea is another common side effect of Polivy, affecting up to 70% of patients. This can be caused by the drug's effect on the gut microbiome.
*

Fatigue

Fatigue is a common side effect of Polivy, affecting up to 60% of patients. This can be caused by the drug's effect on the body's energy levels.
*

Neutropenia

Neutropenia is a condition characterized by a low white blood cell count, which can increase the risk of infection. This side effect is common in patients taking Polivy, affecting up to 50% of patients.
*

Anemia

Anemia is a condition characterized by a low red blood cell count, which can cause fatigue and shortness of breath. This side effect is common in patients taking Polivy, affecting up to 40% of patients.
*

Thrombocytopenia

Thrombocytopenia is a condition characterized by a low platelet count, which can increase the risk of bleeding. This side effect is common in patients taking Polivy, affecting up to 30% of patients.

Other Side Effects of Polivy

In addition to the common side effects mentioned above, Polivy can also cause other side effects, including:

*

Infusion Reactions

Infusion reactions can occur during or after treatment with Polivy, causing symptoms such as fever, chills, and nausea.
*

Increased Risk of Infections

Polivy can increase the risk of infections, including pneumonia, sepsis, and other bacterial infections.
*

Increased Risk of Bleeding

Polivy can increase the risk of bleeding, including gastrointestinal bleeding and hemorrhage.
*

Increased Risk of Thrombosis

Polivy can increase the risk of thrombosis, including deep vein thrombosis and pulmonary embolism.

Managing Side Effects of Polivy

To manage side effects of Polivy, your healthcare provider may recommend:

*

Medications to Prevent Nausea and Vomiting

Medications such as ondansetron and granisetron can be used to prevent nausea and vomiting.
*

Medications to Prevent Diarrhea

Medications such as loperamide can be used to prevent diarrhea.
*

Medications to Prevent Fatigue

Medications such as erythropoietin can be used to prevent fatigue.
*

Medications to Prevent Infections

Medications such as antibiotics can be used to prevent infections.

Conclusion

Polivy is a powerful treatment option for certain types of non-Hodgkin lymphoma. While it can cause common side effects such as nausea and vomiting, diarrhea, fatigue, neutropenia, anemia, and thrombocytopenia, these side effects can be managed with medication and other treatments. It is essential to discuss the potential side effects of Polivy with your healthcare provider before starting treatment.

Key Takeaways

* Polivy is a monoclonal antibody-drug conjugate used to treat certain types of non-Hodgkin lymphoma.
* The most common side effects of Polivy include nausea and vomiting, diarrhea, fatigue, neutropenia, anemia, and thrombocytopenia.
* Other side effects of Polivy include infusion reactions, increased risk of infections, increased risk of bleeding, and increased risk of thrombosis.
* Medications can be used to manage side effects of Polivy.

FAQs

Q: What is Polivy used to treat?
A: Polivy is used to treat certain types of non-Hodgkin lymphoma.

Q: What are the most common side effects of Polivy?
A: The most common side effects of Polivy include nausea and vomiting, diarrhea, fatigue, neutropenia, anemia, and thrombocytopenia.

Q: Can Polivy cause infusion reactions?
A: Yes, Polivy can cause infusion reactions, including fever, chills, and nausea.

Q: Can Polivy increase the risk of infections?
A: Yes, Polivy can increase the risk of infections, including pneumonia, sepsis, and other bacterial infections.

Q: Can Polivy increase the risk of bleeding?
A: Yes, Polivy can increase the risk of bleeding, including gastrointestinal bleeding and hemorrhage.

Q: Can Polivy increase the risk of thrombosis?
A: Yes, Polivy can increase the risk of thrombosis, including deep vein thrombosis and pulmonary embolism.

Sources:

1. FDA Label: Polivy (polatuzumab vedotin-piiq) [package insert]. New York, NY: Genentech, Inc.; 2020.
2. ClinicalTrials.gov: A Study of Polatuzumab Vedotin (PGV) in Combination With Rituximab and Bendamustine in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (POLARIX). Bethesda, MD: National Library of Medicine; 2020.
3. DrugPatentWatch.com: Polatuzumab Vedotin-Piiq (Polivy). [cited 2023 Mar 15]. Available from: <https://www.drugpatentwatch.com/drug/Polivy>
4. National Cancer Institute: Polatuzumab Vedotin. [cited 2023 Mar 15]. Available from: <https://www.cancer.gov/about-cancer/treatment/drugs/polatuzumab-vedotin>